glecaprevir/pibrentasvir vs naltrexone
Side-by-side comparison of glecaprevir/pibrentasvir and naltrexone. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
There is insufficient information to make a recommendation regarding the concomitant use of naltrexone with MAVYRET.
Recommendation: Talk to your doctor before taking these together because the safety of this combination is not yet known.
Mavyret
Vivitrol, ReVia
Mavyret is a medicine used to treat hepatitis C (HCV) in adults and children 3 years and older. It contains two drugs, glecaprevir and pibrentasvir, that work together to stop the virus from multiplying.
Naltrexone is a medicine that can help treat alcohol and opioid dependence. It works by blocking the effects of opioids in your body.
Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6. It can be used in people without cirrhosis or with compensated cirrhosis. Mavyret can also treat genotype 1 in people who have already been treated with certain other HCV medicines.
Naltrexone is used to treat alcohol dependence and to block the effects of opioid drugs. It is important to use naltrexone as part of a complete treatment plan. This plan should include counseling and support to help you stay sober or opioid-free.
Mavyret contains glecaprevir and pibrentasvir. Glecaprevir blocks a protein called NS3/4A protease that the virus needs to multiply. Pibrentasvir blocks a protein called NS5A, also needed for the virus to multiply. By blocking these proteins, Mavyret stops the hepatitis C virus from spreading in your body.
Naltrexone blocks the effects of opioids by attaching to opioid receptors in the brain. This prevents opioids from having their usual effects, like pain relief or feelings of euphoria. By blocking these effects, naltrexone can help reduce cravings for alcohol or opioids.
- • Headache
- • Feeling tired
- • Nausea
- • Nausea
- • Headache
- • Fatigue
- • Insomnia
- • Anxiety
- Feeling tired 2,561
- Headache 2,203
- Nausea 1,125
- Itching 653
- Diarrhea 477
- Reaction at the injection site 4,407
- Pain at the injection site 3,111
- Feeling sick to your stomach 2,094
- Alcohol addiction 1,942
- Lump at the injection site 1,895
Mavyret can cause hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for hepatitis B before you start Mavyret. They will also monitor you during and after treatment.
Naltrexone can cause serious withdrawal symptoms if you are still using opioids. Make sure you are opioid-free for at least 7 to 10 days before starting naltrexone. If you experience severe withdrawal symptoms, seek medical help right away.
It is not known if Mavyret will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Mavyret passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Mavyret.
It is not known if naltrexone is safe to use during pregnancy. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if naltrexone passes into breast milk, so talk to your doctor if you are breastfeeding.
How to Read This glecaprevir/pibrentasvir vs naltrexone Comparison
glecaprevir/pibrentasvir is classified in the NS3/4A/NS5A Inhibitor (HCV) drug class, while naltrexone sits within the Opioid Antagonist class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, glecaprevir/pibrentasvir has 7,019 submissions while naltrexone has 13,449. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to there is not enough research yet to know exactly how these two drugs affect each other in the body.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between glecaprevir/pibrentasvir and naltrexone - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.